1. Home
  2. INBS vs DRMA Comparison

INBS vs DRMA Comparison

Compare INBS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.61

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBS
DRMA
Founded
2016
2014
Country
United States
United States
Employees
N/A
9
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
4.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
INBS
DRMA
Price
$2.61
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
75.3K
72.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
68.65
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
N/A
Revenue This Year
$778.48
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.59
52 Week High
$24.90
$7.33

Technical Indicators

Market Signals
Indicator
INBS
DRMA
Relative Strength Index (RSI) 35.94 45.66
Support Level $2.42 $1.13
Resistance Level $7.25 $1.40
Average True Range (ATR) 0.23 0.09
MACD 0.07 0.00
Stochastic Oscillator 20.27 28.37

Price Performance

Historical Comparison
INBS
DRMA

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: